Journal Article
. 2020 Jan;10(1).
doi: 10.1038/s41598-020-58007-5.

Impact of deviation from guideline recommended treatment on breast cancer survival in Asia

Peh Joo Ho 1 Samuel Guan Wei Ow 2 Yirong Sim 3 Jenny Liu 4 Swee Ho Lim 5 Ern Yu Tan 6 Su-Ming Tan 7 Soo Chin Lee 2 Veronique Kiak-Mien Tan 3 Yoon-Sim Yap 8 Wen Yee Chay 8 Benita Kiat Tee Tan 3 Fuh Yong Wong 3 Jingmei Li 9 Mikael Hartman 4 
Affiliations
  • PMID: 31992769
  •     42 References

Abstract

Breast cancer survival has improved with significant progress in treatment and disease management. However, compliance with treatment varies. Treatment guidelines for older patients are unclear. We aim to identify predictors of noncompliance with recommended therapy in a large breast cancer population and assess the impact of noncompliance on survival. Our study included 19,241 non-metastatic female breast cancer patients, of whom 3,158 (16%) died within 10 years post-diagnosis (median survival = 5.8 years). We studied the association between treatment noncompliance and factors with logistic regression, and the impact of treatment noncompliance on survival with a flexible parametric survival model framework. The highest proportion of noncompliance was observed for chemotherapy (18%). Predictors of noncompliance with chemotherapy, radiotherapy and endocrine therapy included age, tumor size, nodal involvement and subtype (except radiotherapy). Factors associated with not receiving surgery included age and subtype. Treatment noncompliance was associated with worse overall survival for surgery (HR: 2.26 [1.80-2.83]), chemotherapy (1.25 [1.11-1.41]), radiotherapy (2.28 [1.94-2.69]) and endocrine therapy (1.70 [1.41-2.04]). Worse survival was similarly observed in older patients for whom guidelines generally do not apply. Our results highlight the importance of following appropriate treatment as recommended by current guidelines. Older patients may benefit from similar recommendations.

Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile.
V Duric, M Stockler.
Lancet Oncol, 2002 Mar 21; 2(11). PMID: 11902540
Review.
Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival.
Elisabeth Chéreau, Charles Coutant, +5 authors, Roman Rouzier.
Clin Breast Cancer, 2011 Mar 23; 11(1). PMID: 21421522
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Prevalence and Determinants of Adherence to Oral Adjuvant Endocrine Therapy among Breast Cancer Patients in Singapore.
Eskinder Eshetu Ali, Ka Lok Cheung, +3 authors, Lita Chew.
Asia Pac J Oncol Nurs, 2017 Oct 03; 4(4). PMID: 28966955    Free PMC article.
Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
Allison W Kurian, Irina Bondarenko, +7 authors, Steven J Katz.
J Natl Cancer Inst, 2017 Dec 14; 110(5). PMID: 29237009    Free PMC article.
Reducing Overtreatment of Cancer With Precision Medicine: Just What the Doctor Ordered.
Steven J Katz, Reshma Jagsi, Monica Morrow.
JAMA, 2018 Feb 23; 319(11). PMID: 29470568
Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer.
Rahul Ladwa, Timothy Kalas, +3 authors, Jasotha Sanmugarajah.
Clin Breast Cancer, 2018 May 21; 18(5). PMID: 29778788
Receipt of Guideline-Concordant Care Among Older Women With Stage I-III Breast Cancer: A Population-Based Study.
Traci LeMasters, S Suresh Madhavan, +3 authors, Dustin Long.
J Natl Compr Canc Netw, 2018 Jun 13; 16(6). PMID: 29891521    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
Racial disparities in guideline-concordant cancer care and mortality in the United States.
Penny Fang, Weiguo He, +5 authors, Grace L Smith.
Adv Radiat Oncol, 2018 Sep 12; 3(3). PMID: 30202793    Free PMC article.
Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Albert J Farias, Wen-Hsing Wu, Xianglin L Du.
BMC Cancer, 2018 Dec 06; 18(1). PMID: 30514270    Free PMC article.
Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
Daniel Herr, Manfred Wischnewsky, +10 authors, Achim Wöckel.
PLoS One, 2019 Jul 10; 14(7). PMID: 31283775    Free PMC article.
Ethnic differences in survival after breast cancer in South East Asia.
Nirmala Bhoo-Pathy, Mikael Hartman, +8 authors, Helena M Verkooijen.
PLoS One, 2012 Mar 01; 7(2). PMID: 22363531    Free PMC article.
Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes.
Ross Lawrenson, Chunhuan Lao, +8 authors, Marion Kuper-Hommel.
Cancer Causes Control, 2017 Oct 14; 28(12). PMID: 29027594
Breast cancer survival, survival disparities, and guideline-based treatment.
Deirdre A Hill, Sarah Friend, +4 authors, Melanie Royce.
Breast Cancer Res Treat, 2018 Mar 24; 170(2). PMID: 29569018    Free PMC article.
Refusal of Cancer-Directed Surgery by Breast Cancer Patients: Risk Factors and Survival Outcomes.
Apostolos Gaitanidis, Michail Alevizakos, +3 authors, Michail Pitiakoudis.
Clin Breast Cancer, 2017 Aug 09; 18(4). PMID: 28784267
Outcome analysis of breast cancer patients who declined evidence-based treatment.
Kurian Joseph, Sebastian Vrouwe, +5 authors, Patricia Tai.
World J Surg Oncol, 2012 Jun 28; 10. PMID: 22734852    Free PMC article.